View detailed financial information, real-time news, videos, quotes and analysis on CV Sciences, Inc. (OTC Markets:CVSI). Explore commentary on CV Sciences, Inc. and hear what the experts at We would like to show you a description here but the site won’t allow us. CV Sciences, Inc. - Hold Zacks' proprietary data indicates that CV Sciences, Inc. is currently rated as a Zacks Rank 3 and we are looking for an inline return from the CVSI shares relative to the Zacks Investment Research is releasing its prediction for CVSI based on the 1-3 month trading system that nearly triples the S&P 500. Click here - the CVSI analysis is free » About Price and CV Sciences Inc (CVSI) Reports Q1 Loss, Tops Revenue Estimates by Zacks Equity Research Published on May 08,2020 CV Sciences Inc (CVSI) delivered earnings and revenue surprises of -66.67% and
View detailed financial information, real-time news, videos, quotes and analysis on CV Sciences, Inc. (OTC Markets:CVSI). Explore commentary on CV Sciences, Inc. and hear what the experts at We would like to show you a description here but the site won’t allow us.
CV Sciences (OTCMKTS:CVSI) Rating Lowered to Hold at Zacks ... Shares of CVSI opened at $0.48 on Thursday. The company has a market cap of $47.43 million, a P/E ratio of -3.65 and a beta of 0.06. The stock has a fifty day moving average price of $0.54 and a CV Sciences (OTCMKTS:CVSI) Upgraded to Buy by Zacks ... Zacks Investment Research upgraded shares of CV Sciences (OTCMKTS:CVSI) from a hold rating to a buy rating in a research note released on Friday morning, Zacks.com reports. The firm currently has $0.75 target price on the stock. According to Zacks, “CV Sciences Inc. is a life science company. Its operating segment consists of specialty pharmaceuticals […]
Zacks Investment Research upgraded shares of CV Sciences (OTCMKTS:CVSI) from a hold rating to a buy rating in a report released on Friday morning, Zacks.com reports. They currently have $0.75 price objective on the stock. According to Zacks, “CV Sciences Inc. is a life science company. CV Sciences, Inc. operates as a life science company. It operates through two segments, Consumer Products and Specialty Pharmaceuticals. The Consumer Products segment manufactures, markets, and sells consumer products containing hemp-based cannabidiol oil under the PlusCBD brand in various market sectors, including nutraceutical, beauty care, specialty foods, and vape. CV Sciences Inc. company facts, information and stock details by MarketWatch. View cvsi business summary and other industry information. View CV Sciences Inc CVSI investment & stock information. Get the latest CV Sciences Inc CVSI detailed stock quotes, stock data, Real-Time ECN, charts, stats Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of D. Style Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information
Check out our CVSI stock analysis, current CVSI quote, charts, and historical prices for Cv Sciences Inc stock. View detailed financial information, real-time news, videos, quotes and analysis on CV Sciences, Inc. (OTC Markets:CVSI). Explore commentary on CV Sciences CV Sciences, Inc. (CVSI) Upgraded to Buy: What Does It Mean for the Stock? Zacks 37d. CV Sciences, Inc. (CVSI) Reports Q4 Loss, Lags Revenue Estimates. The average CV Sciences stock price for the last 52 weeks is NaN. Compare CVSI With Other Stocks Nov 8, 2019 CVSI came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of $0.01, compared to earnings of $0.03 per